Form 4 for BRTX BioRestorative Therapies, Inc.
Accepted 2023-01-10 00:00:00 ET · period of report 2023-01-09 · accession 0001567619-23-000770 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-01-10 | 2023-01-09 | BRTX | ALSTODT LANCE | Pres, CEO, COB, Dir | P - Purchase | $3.08 | +100 | 186.1K | +0.1% | +$308 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-01-09 | P | A | 100 | $3.08 | 186,121 | D | — | — | (F1) Includes 100,935 shares received pursuant to an unvested restricted stock unit grant. Such shares vest to the extent of 1,036 shares on January 18, 2023, 1,037 shares on February 18, 2023, 49,949 shares on March 18, 2023 and 48,913 shares on March 18, 2024. |